Pilot Evaluation: Toronto Heart Centre to conduct comparative testing of CardioYieldâ"¢ for enhanced Holter ECG analysis and reporting efficiency. Clinical Workflow Impact: Study to measure time savings, throughput improvements, and analysis quality when using CardioYieldâ"¢ versus current industry-standard software. ...

AngioDynamics, Inc. (NASDAQ:ANGO) reported a narrower-than-expected Q1 fiscal 2026 loss per share of $0.10, beating the Zacks Consensus Estimate.The company's revenue reached $75.71 million, marking a 12.2% year-over-year increase, driven by significant growth in its Med Tech segment.AngioDynamics raised its fiscal year 2026 sales outlook to $308 million to $313 million, reflecting confidence in continued growth.AngioDynamics, Inc. (NASDAQ:ANGO), a prominent figure in the medical technology industry, focuse ...

MESA, AZ / ACCESS Newswire / October 6, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE) announced its plan to benchmark its upcoming AI diagnostic model against the HAM10000 public dermatology dataset to validate its image recognition architecture for detecting various skin lesion types. The benchmarking process will help evaluate model precision, sensitivity, and specificity relative to peer-reviewed standards. ...

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine launches a subscription-based platform designed to empower researchers and developers advancing access and innovation in portable MRI. ...

In the most recent 13F, Terry Smith’s Fundsmith LLP reported a portfolio valued at $23.02 billion, with the top five holdings making up a substantial 43.49% of total assets. Smith, often described as a buy-and-hold investor with a focus on high-quality growth companies, continues to emphasize durable franchises with strong cash generation. Below is a detailed look at each of the top five positions.Meta Platforms Inc. (META) – 11.44%Fundsmith’s largest holding is Meta Platforms, with 3.57M shares worth $2.63 ...

Core Viewpoint - Cognixion has initiated a clinical study to explore the integration of its non-invasive brain-computer interface (BCI) based on EEG with Apple Vision Pro, aiming to provide a new natural interaction method for patients without surgery [2][8] Product and Technology Features - Cognixion's Axon-R platform is a wearable, non-invasive neural interface device that captures and decodes brain activity through advanced EEG measurement and feedback [4] - The study combines Cognixion's platform with Apple Vision Pro's spatial computing and assistive features, emphasizing a "non-surgical, wearable, and everyday" approach, making it easier to promote in clinical and home settings [4][10] Clinical Research Design - The clinical study has begun recruitment and will continue until April 2026, with plans to conduct pivotal clinical trials and apply for FDA approval in 2026 after feasibility studies [5] Interaction and Application - The study aims to validate natural communication capabilities through the combination of EEG signals and eye-tracking, assessing the technology's value in mobile device control, entertainment, education, and work [6] - The focus is on exploring applications for patients with ALS, spinal cord injuries, post-stroke speech disorders, and traumatic brain injuries [6] Company and Collaboration Background - Cognixion, based in Santa Barbara, California, is a startup focused on neural interfaces and assistive technologies, aiming to make brain-computer interfaces accessible as wearable everyday devices [7] Industry Trends - The integration of non-invasive BCI technology with mainstream consumer electronics, represented by Cognixion's collaboration with Apple Vision Pro, signifies a new trend in the BCI market [8] - The opportunity for non-invasive BCI is highlighted as it provides a lower barrier solution compared to implantable BCIs, which are still in early clinical stages [10] - The trend towards multi-modal integration, combining EEG signals with eye-tracking and head posture, is seen as a significant development direction for future BCI technologies [10]

Core Insights - Medical Care Technologies Inc. is exploring the integration of blockchain technology for securing patient medical data in its upcoming medical research application [1] - The use of blockchain is aimed at enhancing the protection of sensitive health information [1] - The initiative aligns with the company's commitment to full HIPAA compliance [1]

Core Points - Ventripoint Diagnostics Ltd. is seeking approval from the TSX Venture Exchange to extend the deadline for its non-brokered private placement of unsecured convertible debentures to November 2, 2025 [1] - The company plans to increase the size of the offering from $500,000 to $560,000 [2] - Each unit in the offering consists of one unsecured convertible debenture with a principal amount of $1,000 and 9,000 common share purchase warrants [2] - The convertible debentures can be converted into common shares at a price of $0.11 per share [3] - Each warrant allows the holder to purchase one common share at a price of $0.14 until December 31, 2027 [3] - The debentures will mature on December 31, 2027, and will bear an interest rate of 10%, payable semi-annually [4] - Proceeds from the offering will be used for operational costs, sales and marketing, hiring key personnel, and general working capital [5] - All securities issued will be subject to a hold period of four months plus one day from the closing date of the offering [6] Company Overview - Ventripoint has established itself as a leader in applying AI technology to echocardiography [8] - The company's VMS+ products utilize proprietary knowledge-based reconstruction technology, providing accurate cardiac measurements comparable to MRI [8] - Ventripoint's products are designed to enhance patient care and are compatible with ultrasound systems from various vendors, supported by regulatory approvals in the U.S., Europe, and Canada [9]

Core Viewpoint - The analysis indicates a positive outlook on AngioDynamics, Inc. (NASDAQ: ANGO) due to its expanding portfolio in medical technology, suggesting potential investment opportunities in the company [1]. Company Summary - AngioDynamics is recognized for its growth in the medical technology sector, which is often overlooked by many investors, particularly in the small- to mid-cap range [1]. - The company has been rated a Buy, reflecting confidence in its future performance and market position [1]. Industry Context - The analysis occasionally includes insights on large-cap companies to provide a broader perspective on equity markets, indicating that AngioDynamics operates within a competitive landscape that includes both small and large players [1].

Core Viewpoint - The analysis indicates a positive outlook for AngioDynamics, Inc. (NASDAQ: ANGO) based on its growing portfolio of medical technology products [1] Company Summary - AngioDynamics is recognized for its focus on medical technology, particularly in the small- to mid-cap sector, which is often overlooked by investors [1] - The company has been rated a Buy, suggesting confidence in its growth potential and market position [1] Industry Context - The analysis occasionally includes insights on large-cap companies to provide a broader perspective on equity markets, indicating a comprehensive approach to market research [1]